Jonathan Cotliar - Oct 6, 2021 Form 4 Insider Report for Science 37 Holdings, Inc. (SNCE)

Role
Chief Medical Officer
Signature
/s/ Christine Pellizzari, Attorney-in-Fact for Jonathan Cotliar
Stock symbol
SNCE
Transactions as of
Oct 6, 2021
Transactions value $
$0
Form type
4
Date filed
10/8/2021, 09:58 PM
Next filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNCE Common Stock Award +533K 533K Oct 6, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNCE Stock Option Award +4.54K 4.54K Oct 6, 2021 Common Stock 4.54K $0.85 Direct F2, F3
transaction SNCE Stock Option Award +10.7K 10.7K Oct 6, 2021 Common Stock 10.7K $0.85 Direct F2, F4
transaction SNCE Stock Option Award +295K 295K Oct 6, 2021 Common Stock 295K $0.40 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the business combination of LifeSci Acquisition II Corp and Science 37, Inc. ("Old Science 37"), as contemplated by that certain agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), each share of common stock of Old Science 37 outstanding immediately prior to the effective time of the business combination was converted into approximately 1.8153 shares of the Issuer's Common Stock.
F2 Pursuant to the business combination of LifeSci Acquisition II Corp and Science 37, Inc. ("Old Science 37"), as contemplated by that certain agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), (a) each share of common stock of Old Science 37 outstanding immediately prior to the effective time of the business combination was converted into approximately 1.8153 shares of the Issuer's Common Stock, (b) (the "Conversion Ratio"); and (b) each outstanding stock option of Old Science 37 was converted into a corresponding option to purchase shares of the Issuer's Common Stock as adjusted for the Conversion Ratio
F3 Stock Option is currently fully vested and exercisable.
F4 Stock Option is currently vested and exercisable as to 4,882 of the underlying shares, and the remaining shares will vest in equal monthly installments until fully vested on March 9, 2022, subject to the applicable executive's continued service through the vesting date.
F5 Stock Option is currently vested and exercisable as to 68,074 of the underlying shares, and the remaining shares will vest in equal monthly installments until fully vested on June 6, 2023, subject to the applicable executive's continued service through the applicable vesting date.